Skip to main content
. 2023 Jul 25;382:e075015. doi: 10.1136/bmj-2023-075015

Fig 5.

Fig 5

Risk of adverse events within 28 days of vaccination with a bivalent omicron adapted mRNA booster vaccine as fourth dose in Danish adults aged ≥50 years from 15 September 2022 to 10 December 2022 by type of vaccine received. Each outcome was studied separately, explaining slight differences in denominators owing to different exclusions. *Corresponding number of events and person years are presented in supplementary table S3. NE=not estimable